

Date: November 11, 2021

To, BSE Limited, 25, P. J. Towers, Dalal Street, Mumbai – 400 001 Ref: Company Scrip Code: 532834	To, The Manager, Listing Department, National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 Ref: Symbol: CAMLINFINE Series: EQ
--------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir/Madam,

Sub: Disclosure of events or information under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”)

This is with reference to our intimation dated May 16, 2021 wherein the Company had informed regarding approval of the Committee of the Board of Directors for the strategic investment in AlgalR NutraPharms Private Limited (“AlgalR”) by way of acquisition of equity shares through Primary Subscription and Secondary Purchase. Further, the Company had intimated that upon the consummation of the said transactions of Primary Subscription and Secondary Purchase, the Company will hold 80% of the paid-up capital of AlgalR on a fully diluted basis.

Pursuant to the aforesaid approval of the Committee, the Company on November 11, 2021 has remitted funds towards (i) subscription of equity shares of AlgalR (“Primary Subscription”); and (ii) acquisition of equity shares from the existing promoters (Secondary Purchase).

The details required under the SEBI LODR Regulations are annexed herewith.

This is for your information and record please.

Thanking you,


For Camlin Fine Sciences Limited



Santosh Parab
Chief Financial Officer

 **Registered Office:**
Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400 093, India.
CIN: L74100MH1993PLC075361 | ISO 22000 Certified Company

 +91 22 6700 1000

 +91 22 2832 4404

 corporate@camlinfs.com


 www.camlinfs.com

Annexure

Sr. No.	Particulars	Details
a.	Name of the target entity	AlgalR NutraPharms Private Limited ("AlgalR")
b.	Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group companies have any interest in the entity being acquired	The acquisition does not fall within related party transaction(s). The promoter / promoter group have no interest in AlgalR.
c.	Industry to which the entity being acquired belongs	Nutraceuticals and Pharma
d.	Objects and Effects of acquisition	AlgalR provides an opportunity to the Company for expanding its footprint into the Nutraceuticals segment. Upon consummation of the transaction, the Company shall become the holder of 80% of the paid-up share capital of AlgalR on a fully diluted basis.
e.	Brief details of any governmental regulatory approvals required for the acquisition	None
f.	Indicative time period for completion of acquisition	Within 30 days
g.	Nature of consideration (Cash Consideration or Share Swap and details of the same)	Cash
h.	Cost of acquisition or the price at which the shares are acquired	INR 70/- per equity share.
i.	Percentage of Shareholding/control acquired and/or number of shares acquired	The Company will be acquiring 80% of the issued and paid-up share capital of AlgalR on a fully diluted basis.
j.	Brief background about the entity acquired in terms of products/line of business acquired, history of last 3 years turnover, country in which the acquired entity has presence.	AlgalR was incorporated on 24 th July 2014. It is a manufacturer of Algal Omega-3 fatty acids, particularly Docosahexaenoic acid (DHA) and Eicosapentaenoic acid (EPA) from microalgae, which are considered 100% Vegetarian. Omega-3 fatty acids play an important role in the human metabolism and has been associated with a number of health benefits. These products are

 **Registered Office:**
 Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400 093, India.
 CIN: L74100MH1993PLC075361 | ISO 22000 Certified Company

 +91 22 6700 1000


 +91 22 2832 4404

 corporate@camlinfs.com

 www.camlinfs.com


		<p>manufactured in compliance with the set industrial norms, FSSAI, and ISO 22000:2005 standards using a patented technology in a state-of-the-art production system located in Southern part of India.</p> <p>Revenue from operations for the past 3 years:</p> <p>FY 2020-21: INR 59,10,754/- FY 2019-20: INR 55,60,392/- FY 2018-19: INR 4,43,250/-</p>
--	--	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------


For Camlin Fine Sciences Limited



Santosh Parab
Chief Financial Officer

 **Registered Office:**
Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400 093, India.
CIN: L74100MH1993PLC075361 | ISO 22000 Certified Company

 +91 22 6700 1000

 +91 22 2832 4404

 corporate@camlins.com

 www.camlins.com